International Isotopes, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 41 full-time employees. The firm's segments include Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Device Products and Fluorine Products. Theranostics Products segment includes production and distribution of its generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications. Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. Fluorine Products segment is involved in the production of small-scale qualification samples of high-purity fluoride gas for various industrial applications. The company is working to launch the RadVent brand of medical devices.
Follow-Up Questions
International Isotopes Inc (INIS) 的本益比是多少?
International Isotopes Inc 的本益比是 3691.183
International Isotopes Inc 的 CEO 是誰?
Mr. Shahe Bagerdjian 是 International Isotopes Inc 的 President,自 2023 加入公司。
INIS 股票的價格表現如何?
INIS 的當前價格為 $0.0566,在上個交易日 decreased 了 0%。
International Isotopes Inc 的主要業務主題或行業是什麼?
International Isotopes Inc 屬於 Life Sciences Tools & Services 行業,該板塊是 Health Care